Follistatin

Discovery and Structure

Follistatin (FST) was first isolated in 1987 by Ueno and colleagues from ovarian follicular fluid, where it was identified as an inhibitor of pituitary FSH secretion — the origin of its name. The protein turned out to be considerably more interesting than that initial role suggested. Follistatin is a secreted glycoprotein that binds and neutralizes multiple members of the TGF-β superfamily, most notably activin and — critically for the peptide-research community — myostatin (GDF-8).

Alternative splicing of the FST gene produces two principal isoforms: follistatin-288 (FS-288), which binds heparan sulfate on cell surfaces and is largely tissue-localized, and follistatin-315 (FS-315), the predominant circulating form. A third research-relevant variant, follistatin-344 (FS-344), is the precursor used in gene-therapy constructs and is often what is loosely labeled "FS-344" in research-chemical markets.

Mechanism of Action

Follistatin's core action is high-affinity binding of activin and myostatin, which sequesters these ligands and prevents them from engaging their type II receptors on target tissues:

• Myostatin neutralization removes a major negative regulator of skeletal muscle mass. Myostatin normally limits muscle growth; blocking it permits hypertrophy and, in animal models, produces dramatic increases in lean mass. The naturally occurring "double-muscled" cattle breeds (Belgian Blue, Piedmontese) carry loss-of-function myostatin mutations and demonstrate the phenotype's extreme end.
• Activin inhibition affects FSH secretion, reproductive tissue function, and inflammation.
• GDF-11 binding contributes to its broader effect on tissue homeostasis and aging research.

Evidence Base

The follistatin literature bifurcates sharply into two streams. The preclinical and translational gene-therapy stream is serious, peer-reviewed, and ongoing — notably work led by Nationwide Children's Hospital and Sarepta Therapeutics using AAV-delivered follistatin in Becker muscular dystrophy and inclusion body myositis. Phase 1 and Phase 2 trials have documented improved six-minute walk test performance and muscle biopsy changes consistent with target engagement. This is not the same product as injected follistatin peptide, but it is the highest-quality evidence that sustained follistatin elevation produces measurable muscle effects in humans.

The research-chemical injectable stream — FS-344 and FS-315 sold as peptides — has essentially no published human data. The rationale extrapolates from the gene-therapy and rodent work, but injectable recombinant follistatin has a short circulating half-life (minutes to a few hours depending on isoform), and whether bolus subcutaneous dosing produces meaningful myostatin suppression in humans is unclear.

Practical Considerations

Community protocols for injectable follistatin typically use 50–100 mcg daily over 10–30 day courses, often positioned as a "muscle growth" peptide alongside ipamorelin and CJC-1295. The honest translation between the gene-therapy evidence and short-course peptide injection is weak — sustained expression of follistatin over months is not equivalent to pulsed peptide exposure.

Because follistatin binds activin, sustained high exposure could theoretically suppress FSH and affect fertility. Reported anecdotal effects of injectable follistatin include transient LDL elevation and flu-like symptoms, but no controlled dose-ranging data exist for the injectable product.

Safety and Regulatory Status

Injectable follistatin is not FDA-approved for any indication. Gene-therapy follistatin constructs are still in clinical development and are regulated under investigational-new-drug protocols. The research-chemical injectable product falls outside any regulated supply chain, and purity, peptide-isoform identity, and endotoxin status vary substantially across suppliers. Follistatin is banned by WADA under the S4.3 "myostatin function altering" category.

Potential safety concerns specific to myostatin inhibition — beyond supply-chain issues — include theoretical risks to cardiac tissue (myostatin regulates cardiomyocyte size), tendon strength relative to rapidly growing muscle, and unknown long-term effects on cancer biology, since TGF-β family signaling has complex roles in tumor suppression and progression.

The Bottom Line

Follistatin is a legitimate and exciting target in muscle-wasting disease research — the gene-therapy program is one of the more interesting stories in the myostatin-pathway literature. The injectable peptide sold to bodybuilding and longevity users is a speculative extrapolation from that work, with effectively no human efficacy data and meaningful theoretical risks that the short-course protocols in circulation do not address.